Y-MABS THERAPEUTICS INC. - COMMON STOCK
6.2400
14-二月-25 16:45:00
15 分钟延时
股票
+0.0700
+1.13%
今日范围
6.1700 - 6.6500
ISIN
N/A
来源
NASDAQ
-
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
01 8月 2023 16:05:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 5月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 5月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 5月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
08 5月 2023 16:01:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
28 4月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 4月 2023 09:00:02 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 4月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
30 3月 2023 16:01:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
21 3月 2023 16:01:00 条件 Nasdaq GlobeNewswire
-
02 2月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
04 1月 2023 16:01:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 1月 2023 09:00:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
21 12月 2022 09:00:00 条件 Nasdaq GlobeNewswire
-
16 12月 2022 16:01:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces Pipeline Update
14 12月 2022 09:00:01 条件 Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
08 12月 2022 09:00:00 条件 Nasdaq GlobeNewswire
-
Y-mAbs to Host Annual Research and Development Day in New York
06 12月 2022 09:00:01 条件 Nasdaq GlobeNewswire
-
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
01 12月 2022 17:34:16 条件 Nasdaq GlobeNewswire
-
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
07 11月 2022 16:01:00 条件 Nasdaq GlobeNewswire